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Introduction
Current cancer chemotherapy targets proliferating and metaboli-
cally active cancer cells and efficiently reduces the tumor load. 
However, frequent relapses suggest the persistence of residual 
cancer stem cells that escaped treatment possibly due to a protec-
tive microenvironment that blunts their chemosensitivities (1–3). 
The reliance of cancer stem cells on their microenvironments and 
on non–cell-autonomous pathways (3) together with the failure of 
mainstream chemotherapy in a significant proportion of patients 
points to an urgent need for novel drug screening strategies 
designed to target cancer stem cells in their niche.
Recent evidence based on ultradeep sequencing of targeted 
genomic regions in acute leukemias revealed the existence of long-
lasting preleukemic hematopoietic stem cells within the bulk of 
leukemic cells that serve as a reservoir for disease progression (4, 
5). While these cells are believed to resist therapy, direct evidence 
for their distinctive chemosensitivities compared with leukemic 
blasts remains to be documented. In addition, treatment is limited 
by indiscriminate toxicity toward normal hematopoietic stem cells 
(HSCs). Therefore, the current challenge is to specifically target 
these preleukemic stem cells (pre-LSCs) that represent an extreme-
ly rare subpopulation in patients (4–7) and are not easily amenable 
to high-throughput screening (HTS) for novel drug discovery.
Acute lymphoblastic leukemia (ALL) is the most frequent 
pediatric cancer. T cell ALL (T-ALL), representing 15%–20% of 
ALL, can be classified into major molecular subgroups charac-
terized by overexpression of oncogenic transcription factors (8, 
9) that include SCL/TAL1, a member of the basic helix-loop-
helix (bHLH) family, and LMO1 and LMO2, two LIM-only pro-
teins (10). We and others have previously shown that oncogenic 
transcription factors in acute leukemia reprogram non–stem 
cell populations into aberrantly self-renewing pre-LSCs (7, 
11–14). Using transgenic mouse models expressing the human 
SCL and LMO1 oncogenes in the thymus (15, 16), we showed 
that pre-LSCs remain dependent on physiological signaling 
from the microenvironment, specifically on activation of the 
NOTCH1/MYC axis (14). Our observations underscore the crit-
ical importance of a niche-based assay for pre-LSCs, to allow 
for the discovery of new classes of antileukemic drugs beyond 
those that have been identified so far using standard cell line 
screening. A challenge in HTS is the necessary miniaturization 
Current chemotherapies for T cell acute lymphoblastic leukemia (T-ALL) efficiently reduce tumor mass. Nonetheless, disease 
relapse attributed to survival of preleukemic stem cells (pre-LSCs) is associated with poor prognosis. Herein, we provide direct 
evidence that pre-LSCs are much less chemosensitive to existing chemotherapy drugs than leukemic blasts because of a 
distinctive lower proliferative state. Improving therapies for T-ALL requires the development of strategies to target pre-LSCs 
that are absolutely dependent on their microenvironment. Therefore, we designed a robust protocol for high-throughput 
screening of compounds that target primary pre-LSCs maintained in a niche-like environment, on stromal cells that were 
engineered for optimal NOTCH1 activation. The multiparametric readout takes into account the intrinsic complexity of primary 
cells in order to specifically monitor pre-LSCs, which were induced here by the SCL/TAL1 and LMO1 oncogenes. We screened a 
targeted library of compounds and determined that the estrogen derivative 2-methoxyestradiol (2-ME2) disrupted both cell-
autonomous and non–cell-autonomous pathways. Specifically, 2-ME2 abrogated pre-LSC viability and self-renewal activity in 
vivo by inhibiting translation of MYC, a downstream effector of NOTCH1, and preventing SCL/TAL1 activity. In contrast, normal 
hematopoietic stem/progenitor cells remained functional. These results illustrate how recapitulating tissue-like properties of 
primary cells in high-throughput screening is a promising avenue for innovation in cancer chemotherapy.
High-throughput screening in niche-based assay 
identifies compounds to target preleukemic stem cells
Bastien Gerby,1,2 Diogo F.T. Veiga,1,2 Jana Krosl,1 Sami Nourreddine,1,2 Julianne Ouellette,1,2 André Haman,1,2 Geneviève Lavoie,1,2 
Iman Fares,1 Mathieu Tremblay,1,2 Véronique Litalien,1 Elizabeth Ottoni,1,2 Milena Kosic,1,2 Dominique Geoffrion,1,2 Joël Ryan,1  
Paul S. Maddox,3 Jalila Chagraoui,1 Anne Marinier,1 Josée Hébert,4 Guy Sauvageau,1,4 Benjamin H. Kwok,1,2  
Philippe P. Roux,1,2 and Trang Hoang1,2,5
1Institute for Research in Immunology and Cancer, and 2Molecular Biology Program, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada. 3Department of Biology, University of North 
Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 4Leukemia Cell Bank of Quebec, Maisonneuve-Rosemont Hospital, Department of Medicine, and 5Department of Pharmacology and Physiology and 
Department of Biochemistry, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
Note regarding evaluation of this manuscript: Manuscripts authored by scientists 
associated with Duke University, The University of North Carolina at Chapel Hill, 
Duke-NUS, and the Sanford-Burnham Medical Research Institute are handled not by 
members of the editorial board but rather by the science editors, who consult with 
selected external editors and reviewers.
Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: January 13, 2016; Accepted: September 22, 2016.
Reference information: J Clin Invest. 2016;126(12):4569–4584. doi:10.1172/JCI86489.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 5 7 0 jci.org   Volume 126   Number 12   December 2016
Figure 1. Proliferative leukemic blasts outcompete pre-LSCs and are more sensitive to chemotherapeutic agents. (A and B) Pre-LSCs are more resistant to the 
treatment than leukemic cells. Pre-LSCs or fully transformed SCL-LMO1 leukemic blasts were cocultured on OP9-DL1 stromal cells and treated with camptothecin 
(Campto, A, left panel), doxorubicin (DOXO, A, right panel), or dexamethasone (DEXA, B) for 3 days. Viable T cells were assessed by FACS (mean ± SEM compared 
with controls, n = 6, *P ≤ 0.05). Representative of 2 independent experiments. (C) Inverse correlation between pre-LSC gene signature (14) and tumor load in 
Cd3e–/–SCL-LMO1 T-ALLs. Data from RNA sequencing of Cd3e–/–SCL-LMO1 T-ALLs were ranked according to the tumor load (Supplemental Figure 1A). (D) Gene 
set enrichment analysis for genes that are upregulated in leukemic blasts compared with pre-LSCs. Top panel: The top 7 gene ontology categories significantly 
enriched in T-ALL blasts (FWER P < 0.03). Bottom panel: Enrichment plots. (E) Pre-LSCs or leukemic blasts (5 × 104 cells, CD45.2) from Cd3e–/–SCLtgLMO1tg mice or 
WT thymocytes were transplanted into recipient mice (CD45.1). Shown are the percentage of donor T cells (% CD45.2+Thy1.2+) per mouse analyzed 3 and 6 weeks 
later. Horizontal lines, median of thymic engraftment. (F and G) Pre-LSCs exhibit low cell division frequency and are outcompeted by leukemic cells in vitro. SCL-
LMO1 leukemic cells (GFP–) and pre-LSCs (GFP+) were mixed in equal proportion and cultured for 3 days on OP9-DL1; GFP– and GFP+ cells were analyzed before (gray 
curve) and after (black curve) coculture (F, n = 3). The numbers of divisions per field of observation during 20 hours (G, top panel, n = 4) and each individual division 
observed at the indicated times in a total of 6 fields of view (G, bottom panel, n = 5–23) were then compared between GFP– and GFP+ cells by time-lapse imaging 
(20 hours). ***P ≤ 0.001. Representative of 2 independent experiments.
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initiating event is the establishment of an aberrant population of 
pre-LSCs found in both healthy and leukemic twins, with addi-
tional transforming event(s) in the leukemic patient (7). The iden-
tification of activating NOTCH1 mutations in over 60% of T-ALL 
patient samples in all molecular subgroups (17) rapidly led to the 
design of high-potency γ-secretase inhibitors (GSIs) targeting 
NOTCH1 signaling. GSIs are well tolerated with staggered dosing 
of a stromal-based coculture assay into a reproducible assay 
with a quantitative readout.
At the cellular level, these pre-LSCs serve as a reservoir for 
acquisition of Notch1 gain-of-function mutations (16) that reca-
pitulate those identified in the human disease (17). Therefore, 
the mouse model closely mimics the leukemogenic process in 
humans, initially reported in monochorionic twins in which the 
Figure 2. High-throughput assay for primary pre-LSCs in thymic-like microenvironment. (A and B) Generation of an optimal MS5-DL4 stromal cell line 
for pre-LSC viability. Following DL4 gene transfer, MS5 stromal cells were assessed for DL4 surface expression levels. Three MS5 subclones were purified 
according to levels of DL4 expression (low, medium, and high) (A). DN3 preleukemic SCLtgLMO1tg thymocytes were cocultured with MS5-CTL or MS5-DL4lo, 
-DL4med, or -DL4hi stromal cells during 5 days, and the absolute number of DN3 cells was assessed using FACS. Each dot represents an individual well, and 
dashed lines represent the mean for each condition (B). (C) Purified DN3 WT and preleukemic SCLtgLMO1tg thymocytes were cocultured with MS5-DL4lo 
stromal cells. DN3-derived thymocytes were immunophenotyped 5 days later using the CD4, CD8, CD25, and CD44 markers. (D) Miniaturized coculture 
system for HTS-FACS in 384-well plate. The proportion of DN3 (left panel) and DP (right panel) thymocytes was then assessed using HTS-FACS, and assay 
reproducibility was calculated. Each dot represents an individual well. Solid lines and dashed lines represent the mean and 3-fold the SD, respectively. The 
Z′ factor is a statistical measure of the robustness of the HTS assay (ideally between 0.5 and 1). Representative of 3 independent experiments. (E and 
F) DN3 preleukemic SCLtgLMO1tg thymocytes were cocultured with MS5-DL4lo stromal cells for 5 days in the presence or absence (Vehicle) of γ-secretase 
inhibitor (GSI, 1 μM), and the absolute number of DN3 cells was assessed using HTS-FACS. Representative FACS analysis of DN population is shown (E) 
together with assay reproducibility (F).
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than pre-LSCs, hence their higher sensitivities to topoisomerase 
inhibitors. The enrichment in cell cycle genes was manifested 
in vivo by the kinetic of thymic reconstitution after transplanta-
tion into sublethally irradiated congenic recipient mice (Figure 
1E). Within 3 weeks, T-ALL blasts rapidly and massively invaded 
the thymus (Figure 1E), spleen, and BM (Supplemental Figure 
1B), while pre-LSCs induced a modest and heterogeneous thy-
mic reconstitution at 3 weeks after transplantation and even at 6 
weeks, without engrafting other organs. As expected, WT thymo-
cytes did not engraft (Figure 1E and Supplemental Figure 1B). To 
directly address the question of whether leukemic blasts are more 
competitive than self-renewing pre-LSCs, we set up an equal-split 
competition in which equal proportions (50%) of GFP+ pre-LSCs 
from SIL-SCL Lck-LMO1 double-transgenic mice (SCLtgLMO1tg 
mice), which express the human SCL and LMO1 genes, and non-
GFP leukemic cells were cultured on OP9-DL1 (Figure 1F). Within 
3 days, T-ALL blasts outcompeted pre-LSCs in culture as observed 
by the 3-fold reduction of the proportion of GFP+ pre-LSCs (Figure 
1F). Furthermore, time-lapse imaging (Supplemental Figure 1C) 
of this equal-split competitive assay performed 6 hours after plat-
ing revealed that the division rate of leukemic cells was 4 times 
higher than that of pre-LSCs (Figure 1G).
Together, our results demonstrate that pre-LSCs have a low pro-
liferative status and are more resistant than leukemic cells to cur-
rent chemotherapeutic drugs that target proliferating cells, such as 
doxorubicin. Based on the evidence that pre-LSCs caused relapse 
(6), these cells represent the prime target for new drug development.
Design of a high-throughput screening protocol based on pre-LSC 
viability in a niche-like microenvironment. Several essential param-
eters needed to be integrated into the design of a robust pre-LSC–
based assay for high-throughput screening (HTS). First, pre-LSCs 
are extremely rare in leukemic patient samples, requiring exten-
sive purification by flow cytometry and ultradeep sequencing to 
reveal mutations that occur in these cells (4, 24). This is because 
pre-LSCs are much less competitive than leukemic blasts, as 
shown above, and are highly diluted in the leukemic mass at the 
time of overt leukemia. We took advantage of the preleukemic 
stage in transgenic mouse models to have unrestricted access to 
a reproducible source of pre-LSCs. These cells were harvested at 
weaning, long before the acquisition of secondary mutations and 
leukemia onset (16). Second, we opted for a phenotypic screen 
for several reasons. Given the molecular diversity of T-ALL, we 
reasoned that a phenotypic screen using primary pre-LSCs has a 
higher likelihood of identifying small-molecule inhibitors of self-
renewal, rather than targeting the diversity of oncogenes in the 5 
molecular subgroups of T-ALL (10, 26). In addition, pre-LSCs in 3 
different genetic models of T-ALL of the bHLH subgroup are DN3 
cells (12, 14, 27), and rely on the same self-renewal genes for main-
tenance in vivo (12, 14, 27), reinforcing the suitability of this popu-
lation as target. Moreover, a multiparametric phenotypic screen 
takes into account the heterogeneity of primary cells (14, 28) and 
allows for a quantitative assessment of this specific subset of cells 
based on surface phenotype.
Finally, we previously showed that pre-LSCs conserve their 
dependence on the thymic microenvironment and require cocul-
ture on OP9 stromal cells expressing delta-like 1 (DL1) for surviv-
al in culture (14), much like their normal counterparts (29). We 
in several phase I clinical trials (18, 19). Nonetheless, efficient anti-
leukemic activity might require sustained administration, which 
in turn could be a limiting factor (20). Interestingly, MYC is an 
essential downstream effector of NOTCH1 in T-ALL (21, 22), and 
decreasing Myc expression via a BRD4 inhibitor effectively killed 
leukemia-initiating cells (23).
As discussed above, pre-LSCs are more genetically and pheno-
typically stable (14) than leukemia-propagating cells, which have 
acquired different sets of secondary mutations (16, 24). Impor-
tantly, we provided genetic evidence that self-renewal activity is a 
major determinant of leukemogenesis (14), further underscoring 
the importance of pre-LSC–based screening to identify novel anti-
leukemic compounds. A major advantage of the mouse model is to 
provide unrestricted access to pre-LSCs (14).
Here, we demonstrate that pre-LSCs are much less sensitive 
to current treatment than the leukemic bulk, underscoring the 
importance of novel therapeutic development targeting pre-LSCs. 
We built on mechanistic insight gained in our previous work (14) 
to develop a robust protocol for a phenotypic screen with SCL-
LMO1–induced pre-LSCs cultured within their niche-like micro-
environment. Using FDA-approved compounds and drug-like 
small molecules, we identified 2-methoxyestradiol (2-ME2) as 
a new promising drug that abrogates pre-LSC viability and self-
renewal activity by inhibiting MYC translation and SCL accumu-
lation, thereby antagonizing cell-autonomous as well as non–cell-
autonomous pathways.
Results
Pre-LSC low chemosensitivity and low proliferation rate. Pre-LSCs 
are believed to be chemoresistant and to drive relapse (4, 24), 
although direct evidence for differential chemosensitivity between 
leukemic blasts and pre-LSCs remains to be documented. We took 
advantage of genetic mouse models to directly address the dis-
tinctive properties of pre-LSCs compared with fully transformed 
cells using in vitro and in vivo approaches. We previously showed 
that Cd3e+/+ or Cd3e–/– DN3 thymocytes are the only pre-LSC–
enriched population in mice expressing SCL-LMO1 (14), hereaf-
ter “pre-LSCs.” First, we compared the response of pre-LSCs and 
T-ALL blasts to 2 commonly used inhibitors of DNA replication, 
doxorubicin and camptothecin (Figure 1A). Dose-response curves 
indicate that leukemic cells are 10- to 20-fold more sensitive to the 
2 drugs than pre-LSCs in vitro. Moreover, this difference was also 
observed with dexamethasone (DEXA; Figure 1B), a glucocorti-
coid often used for stratification and treatment of childhood and 
adult T-ALL (25). We conclude that pre-LSCs are poorly respon-
sive to current chemotherapeutic drugs.
We next analyzed by RNA sequencing the transcriptomes of 
3 SCL-LMO1 T-ALLs taken at different stages of leukemia devel-
opment, as assessed by the tumor load. Strikingly, we found that 
the pre-LSC stem cell gene signature (14) was inversely correlated 
with the tumor load, supporting the view that pre-LSCs were pro-
gressively outcompeted by more aggressive leukemic cells (Figure 
1C and Supplemental Figure 1A; supplemental material available 
online with this article; doi:10.1172/JCI86489DS1). Conversely, 
the top gene ontology categories associated with acute leukemia 
compared with the preleukemic stage are mitosis and cell cycle 
(Figure 1D), indicating that leukemic blasts are more proliferative 
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appropriate for a robust chemical HTS assay that requires sev-
eral days of drug exposure. We generated MS5 stromal cell lines 
expressing different levels of the most physiological NOTCH1 
ligand, delta-like 4 (DL4) (31, 32), for coculture with SCLtgLMO1tg 
therefore designed a miniaturized coculture assay for pre-LSC 
viability in their “habitat.” To this end, we replaced OP9 cells, 
which need replating every 3 days, with MS5 stromal cells, which 
can be maintained for at least 7 days in culture (30) and are more 
Figure 3. Small-molecule screening identifies 2-ME2 as an inhibitor of pre-LSCs. (A) Experimental procedure for chemical screening of pre-LSCs. (B) The inhibi-
tion of pre-LSC viability was calculated for each compound (GSI set as 100% and DMSO as 0%; average pre-LSC viability: 0.4%). The top 5% (n = 96) of hits were 
selected. (C) Clustering of 44 selected compounds by structural similarities using the ChemMine tool (http://chemmine.ucr.edu/). The multidimensional scaling 
algorithm maps a compound described by its chemical structure into a 3D space and where neighbor compounds exhibit similar molecular structure. The axes 
(D1, D2, and D3) refer to the dimensions generated by the multidimensional scaling. Black arrow identifies 2-ME2 and gray arrow DEXA. MTDs, microtubule-
targeting drugs. (D) 2-ME2 is the only MTD that does not affect the viability of human HSCs. Human CD34+ peripheral blood was collected from cord blood cells 
and treated with the indicated MTDs at 1 μM during 1 week as described previously (38). Numbers (n = 2) represent the fractions of viable cells compared with 
vehicle control. (E) 2-ME2 structure (top left panel) and dose-response on purified pre-LSCs and DN3 WT thymocytes. The percentages of cell viability are shown 
(right panel, n = 6, *P ≤ 0.05). IC50 was calculated (bottom left panel). Representative of 2 independent experiments. (F) MS5-DL4 stromal cells alone were 
treated in the same conditions. DL4 expression was assessed by FACS (left panel, n = 2), and IC50 for cell viability was calculated (right panel, n = 2). (G) Treated 
and untreated viable cells were then transplanted by limiting dilution assay into recipient mice according to Supplemental Figure 5A. Thymic engraftment was 
analyzed 6 weeks after transplantation, and pre-LSC frequencies were calculated (left panel) by Poisson statistics (CIs in parentheses; ***P ≤ 0.001). Right 
panel: Thymic reconstitution by control or 2-ME2–treated cells.
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pre-LSCs (Figure 2A). We found that MS5-DL4lo cells sustained 
viability of SCLtgLMO1tg pre-LSCs more efficiently than MS5 
expressing higher DL4 levels (Figure 2B). We therefore selected 
MS5-DL4lo (hereafter “MS5-DL4”) for further experiments.
These coculture conditions favored the differentiation of puri-
fied WT DN3 thymocytes to the double-positive (DP) stage within 
5 days (Figure 2C). In contrast, SCL-LMO1–expressing pre-LSCs 
remained blocked at the DN3 stage during the same time frame 
Figure 4. 2-ME2 inhibits the accumulation of SCL protein. (A) Pre-LSCs from SCLtgLMO1tg thymocytes were treated with 2-ME2 (1 μΜ) or DEXA (5 nM) 
for 16 hours, and mRNA levels of SCL and SCL target genes Lyl1 and Hhex were determined by quantitative RT-PCR and normalized to β-actin (mean ± 
SD, n = 3, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001). (B) 2-ME2 inhibits the activity of the SCL transcriptional complex. The Gypa promoter (Gypa-Luc) was used 
as a reporter. Transfected cells were then treated or not (Vehicle) with 2-ME2 (1 μM) or DEXA (2 nM) for 24 hours. Results are expressed as fold activation 
by SCL over the complex without SCL. Data represent the mean ± SD (n = 3, ***P ≤ 0.001). (C) Immunofluorescence of human SCL oncoprotein by flow 
cytometry in pre-LSCs from SCLtgLMO1tg thymocytes treated with the indicated doses of 2-ME2 or not (Vehicle) for 16 hours. DN3 WT thymocytes stained 
with antibody against SCL and cells stained with the secondary antibody only were used as negative controls. (D and E) Real-time imaging of HeLa 
cells expressing SCL-GFP or H2B-RFP in the presence or absence of 2-ME2 (1 μM). Kinetic of GFP (top panels) and RFP (bottom panels) expression in a 
representative treated or untreated cell is shown (D), and the averages of mean fluorescence intensities (MFIs) for each time point were calculated (E). 
MFIs were normalized to the initial intensity of the corresponding cell, which was set as 100%. (F) JURKAT cells were treated with 2-ME2 (1 μM) for the 
indicated times, and nuclear extracts were subjected to immunoblotting. Pol II, RNA polymerase II. (G and H) SCL and histone H3 intracellular immuno-
fluorescence staining in JURKAT cells treated or not with 2-ME2 (1 μM) for 8 hours. The normalized corrected total cell fluorescence (CTCF) per nucleus 
of SCL (n = 27–98, ***P ≤ 0.001) and H3 (n = 42–60) was calculated (G). A representative example of SCL (left panel) and H3 (right panel) expression is 
shown (H). All data shown are representative of 2 independent experiments.
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(Figure 2C), reproducing the differentiation arrest observed in 
vivo (33, 34). Similar results were observed when the assay was 
miniaturized in 384-well format (Figure 2D). Finally, as proof 
of concept for the screen, cultures were exposed to GSI at 1 μM 
or to the vehicle alone (Figure 2, E and F). The drug was added 
12 hours after seeding to allow for pre-LSC–stromal interaction 
before treatment. GSI strongly and reproducibly killed pre-LSCs 
as reported (14), with a robust Z′ factor. By taking into account the 
heterogeneity of primary cells (14, 28) and the necessity of niche-
like microenvironments (14), the designed phenotypic screen 
allows for a quantitative assessment of pre-LSCs. We therefore 
conclude that the assay is suitable for HTS.
Small-molecule screening and identification of an inhibitor of pre-
LSC self-renewal activity. Using the above protocol, we screened a 
library of 1,904 compounds on pre-LSC viability (Figure 3, A and 
B, and Supplemental Figure 2). GSI (14) served as an internal ref-
erence for the screen (Figure 3B and Supplemental Figure 2). The 
majority of tested compounds had no effect on pre-LSC viability, 
underscoring the selectivity of the assay and the specificity of the 
hits. We selected the top 5% of hits that reduced the viability of 
pre-LSCs (Figure 3B, range of 45%–100% inhibition). While our 
assay conditions enable the identification of potential inducers of 
differentiation (Figure 2D and Supplemental Figure 2), no com-
pound was found to overcome the DN to DP differentiation block-
ade imposed by SCL-LMO1. We then applied 3 criteria to filter the 
viability hits. First, compounds were clustered according to struc-
tural similarities (http://chemmine.ucr.edu/). Second, we deter-
mined compound selectivity by comparing our results with those 
obtained in a screen of 20 primary acute myeloid leukemia (AML) 
specimens (Supplemental Table 1), based on the premise that pri-
Figure 5. 2-ME2 inhibits glucocorticoid-resistant T-ALL cells and targets MYC protein synthesis. (A) Dose-response curves of DEXA (left panel) and 2-ME2 
(right panel) of 4 human T-ALL cell lines (JURKAT, KOPTK1, P12-ICHIKAWA, and HPB-ALL) treated for 48 hours (mean ± SEM, n = 3, *P ≤ 0.05). Cell viability 
was assessed by FACS (percent control). (B) Levels of SCL and c-MYC protein expression were determined by Western blot in the 3 indicated T-ALL cell 
lines after total protein extraction. (C–E) JURKAT, KOPTK1, and P12-ICHIKAWA cells were treated for 16 hours with the indicated doses of 2-ME2. Nuclear 
protein extracts were subjected to immunoblotting with the indicated antibodies. α-Actin was used as a loading control. (F) SCL and c-MYC half-lives were 
determined in JURKAT (SCL+c-MYC+) and KOPTK1 (c-MYC+) T-ALL cells by cycloheximide chase and Western blotting according to Supplemental Figure 9D. 
Representative of 2 independent experiments. (G) JURKAT, KOPTK1, and P12-ICHIKAWA cells were treated for 16 hours with the indicated doses of 2-ME2.  
Total protein extracts were subjected to immunoblotting with the indicated antibodies. α-Tubulin was used as a loading control. Representative of 2 inde-
pendent experiments. (H) JURKAT cells were treated with 2-ME2 (3 μM) or not (Vehicle) during 3 hours in the presence of 35S-methionine. SCL (top panel) 
and c-MYC (bottom panel) immunoprecipitation was then performed on labeled proteins. Immunoglobulins were used as control of immunoprecipitation  
(IP CTL). Radiolabeling was revealed using a PhosphorImager. (I) T-ALL blasts from a thymoma of SCLtgLMO1tg mice were treated for 16 hours with the indi-
cated doses of 2-ME2. The human SCL transgene and endogenous c-MYC protein expression levels were then determined by immunoblotting. α-Actin was 
used as a loading control. Representative of 2 independent experiments.
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group included compounds of the phenothiazine family (Figure 
3C and Supplemental Table 2) that were recently identified in a 
screen on MYC-induced T-ALL in zebrafish (35), demonstrating 
the convergence of 2 functional screens, 1 based on whole-animal 
and the other on organotypic cultures of primary cells. Interest-
ingly, glucocorticoids and phenothiazines with the exception of 
perphenazine (35) mostly spared the AML samples that were test-
ed (Supplemental Figure 3), indicating the discriminatory power 
mary human AML cells are significantly different from T-ALL. 
Third, we searched for compounds that spare normal hematopoi-
etic stem/progenitor cells (HSPCs).
Among the viability hits, 42 compounds clustered in 3 major 
groups (Figure 3C and Supplemental Table 2). The first group 
included 15 glucocorticoids, well-known inducers of thymocyte 
apoptosis (Figure 3C and Supplemental Table 2), in particular 
DEXA, which is currently used in T-ALL treatment. The second 
Figure 6. 2-ME2 inhibits T-ALL development without affecting HSC functions in vivo. (A) Experimental procedure to study the in vivo effect of 2-ME2 on 
T-ALL development and HSC functions in a preclinical model. (B) Representative FACS profiles of CD45.2 (donor) and CD45.1 (host) expression in the BM cells 
of mice treated or not (Vehicle) with 2-ME2 (top panel). The expression of CD4/CD8 and c-Kit/Sca-1 markers is shown in CD45.2+ T-ALL cells (middle panel) 
and CD45.1+lineage– cells (bottom panel), respectively. (C) The proportion of T-ALL blasts (CD45.2+) was assessed in the blood (n = 5). Absolute numbers of 
T-ALL blasts (CD45.2+) from the BM, thymus, and spleen were calculated, and pictures of spleens are shown (right panel, n = 5, *P ≤ 0.05, **P ≤ 0.01). (D) 
Kaplan-Meier survival curve of secondary CD45.1+ mice transplanted with T-ALL blasts from 2-ME2–treated and untreated primary recipient (***P ≤ 0.001). 
(E) Absolute numbers of HSC-enriched populations (KSL) from the BM of recipient mice (CD45.1+) were calculated after treatment (n = 5). (F) Absolute 
numbers of donor-derived CD45.1+ HSCs (KSL) and B, myeloid (My), and T cells in the BM of secondary CD45.2+ recipient mice were calculated 14 weeks after 
transplantation (n = 5). Absolute numbers of donor-derived CD45.1+ thymocytes (DN and DP) were calculated in the thymus (n = 5). There was no significant 
difference between controls and 2-ME2–treated conditions. (G) KSL cells from the BM of CD45.2+ mice were purified and treated or not with 2-ME2 (1 μM) on 
MS5-CTL cells during 4 days. Treated and untreated cells were then transplanted into primary and secondary lethally irradiated CD45.1+ mice (left panel,  
n = 3–5). The fold expansions of CD45.2+ KSL cells in the BM were calculated after primary and secondary transplantation. There was no significant differ-
ence between controls and 2-ME2–treated conditions.
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2-ME2 did not affect the numbers of Lin–CD34+ cells compared 
with vehicle-treated control cultures (Figure 3D).
2-ME2 is an estrogen derivative that does not bind the 
estrogen receptor (ER) (36), and estrogens impaired pre-LSCs 
at micromolar concentrations only, well outside their bioactive 
range (Supplemental Figure 4A), indicating an ER-independent 
mechanism. Rather, 2-ME2 is an MTD (36). Dose-response 
curves of 2-ME2 on SCLtgLMO1tg pre-LSCs and normal DN3 thy-
mocytes revealed IC50 of 570 nM and 2 μM, respectively (Figure 
3E), suggesting that the SCL-LMO1 oncogenes sensitize DN3 
of our screening strategy. The whole library included 14 microtu-
bule-targeting drugs (MTDs), and all were active in our assay (Fig-
ure 3C and Supplemental Table 2). Strikingly, 2-methoxyestradiol 
(2-ME2) (36) exhibits structural differences from other MTDs sug-
gesting distinctive properties (Figure 3C). Indeed, 2-ME2 is the 
only MTD for which we observed a differential response in AML 
cells (Supplemental Figure 3). Finally, MTDs have well-known 
toxicities toward HSPCs (37). When tested against purified human 
Lin–CD34+ cells from normal cord blood (38), all MTDs except 
2-ME2 totally inhibited cell viability (Figure 3D). Interestingly, 
Figure 7. 2-ME2 reduces human T-ALL development in xenograft models. (A) Immunophenotype of human T-ALL samples (nos. 14H025 and 14H148) at diagno-
sis and after transplantation in NSG mice. The expression of human CD34/CD7 and CD4/CD8 markers of peripheral blood cells from the patients (left panel) and 
of engrafted human CD45+ T-ALL blasts in the BM of NSG mice 6 weeks after transplantation (right panel) is shown. (B) Purified engrafted human CD45+CD7+ 
T-ALL blasts from patients 14H025 and 14H148 were cocultured on MS5-DL4 stromal cells with a dose-response of 2-ME2 and DEXA for 4 days (n = 3, *P ≤ 0.05). 
The percentages of cell viability are shown for both patients. (C) Blasts from both patients were treated with the indicated doses of 2-ME2 for 16 hours. SCL 
and c-MYC protein expression levels were determined by immunoblotting. (D) Blasts were treated with 1 μM of 2-ME2 during 16 hours, and mRNA expression 
levels of the indicated genes were assessed by quantitative RT-PCR and were normalized to β-actin mRNA (n = 3, **P ≤ 0.01, ***P ≤ 0.001). (E) Experimental 
procedure to study the effect of 2-ME2 on human T-ALL in vivo (left panel). Engrafted T-ALL blasts of both patients were transplanted into secondary NSG mice 
(n = 10), and the proportion of CD45+CD7+ T-ALL blasts in BM aspirations was assessed 3 weeks after transplantation (right panel). (F) Engrafted secondary mice 
were randomly selected for treatment or not (Vehicle, n = 5) with 2-ME2 (40 mg/kg/d, n = 5) using osmotic pumps during 7 days. Human T-ALL reconstitution 
(number of CD45+CD7+ blasts) was monitored by FACS in the BM and the spleen (*P ≤ 0.05, ***P ≤ 0.001).
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Similarly, we found that 2-ME2 decreased endogenous SCL 
protein levels in the SCL+ JURKAT T-ALL cell line, starting at 4–6 
hours after treatment (Figure 4F), exactly as observed with trans-
fected SCL in HeLa cells (Figure 4, D and E). Finally, our immu-
nofluorescence approach confirmed that 2-ME2 decreases SCL 
without modifying histone H3 nuclear expression levels (Figure 
4, G and H). 2-ME2 is a microtubule depolymerizing agent (43). 
To assess the possibility that decreased SCL protein levels could 
be secondary to the perturbation of microtubule dynamics, we 
treated JURKAT T cells with colchicine, a well-characterized 
microtubule depolymerizing drug. While colchicine also inhibited 
cell growth (Supplemental Figure 7A), this occurred in the absence 
of a noticeable effect on SCL protein levels (Supplemental Figure 
7B). Together, these results demonstrate that 2-ME2 impairs SCL 
expression via a colchicine-independent mechanism.
2-ME2 targets 2 pathways: inhibition of SCL and MYC. Resistance 
to glucocorticoids is an adverse prognostic factor in T-ALL both at 
presentation and in relapse (44). We found that 2-ME2 induced 
apoptosis (Supplemental Figure 8A, right panel, and Supplemental 
Figure 8B) and efficiently inhibited the viability of human T-ALL 
cell lines (Figure 5A, right panel) that are either corticosensitive 
(P12-ICHIKAWA) or corticoresistant (JURKAT, KOPTK1, and 
HPB-ALL; Figure 5A, left panel, and Supplemental Figure 8A, left 
panel). Furthermore, 2-ME2 did not modify the corticoresistance 
of JURKAT cells (Supplemental Figure 8C, left panel) nor the cor-
ticosensitivity of P12-ICHIKAWA cells (Supplemental Figure 8C, 
right panel) or of SCL-LMO1 pre-LSCs (Supplemental Figure 8D), 
indicating that the activity of 2-ME2 is cortico-independent.
Consistent with the reported dependence of JURKAT cell 
viability on SCL (45), we observed that SCL protein expression 
in JURKAT cells (Figure 5B) was inhibited by 2-ME2 in a dose-
dependent manner (Figure 5C) in exactly the same range as cell 
growth inhibition (~500 nM). This was associated with the down-
regulation of SCL target gene NKX3.1 (ref. 45 and Supplemental 
Figure 8E, left panel), while SCL mRNA levels were not modified 
by 2-ME2, as observed in pre-LSCs.
We previously showed that the self-renewal node in pre-LSCs 
depends not only on the SCL oncogene but also on the NOTCH1/
MYC axis (14), a non–cell-autonomous pathway triggered by Delta-
like NOTCH1 ligand. Importantly, 2-ME2 did not affect NOTCH1 
target genes including Myc in pre-LSCs (Supplemental Figure 9A), 
ruling out the possibility that 2-ME2 could affect a general mecha-
nism of NOTCH1 activation triggered by ligand endocytosis (46). 
In contrast, 2-ME2 decreased MYC protein levels in pre-LSCs 
(Supplemental Figure 9B). Interestingly, all tested T-ALL cell lines 
exhibit elevated MYC protein levels (Figure 5B and Supplemental 
Figure 9C), which were nearly abrogated by 2-ME2 (Figure 5, C 
and D), whereas MYC mRNA levels were unaffected (Supplemen-
tal Figure 8E, right panel). Strikingly, this inhibitory activity was 
not observed with 2 other factors controlling the self-renewal node 
in normal HSCs, HOXA9 and HOXB4, or with the SCL protein 
partner E2A (Figure 5E). Together, these results indicate a selec-
tive and previously unreported inhibitory effect of 2-ME2 on SCL 
and MYC protein levels.
Decreased SCL and MYC protein levels were not due to pro-
tein degradation, since 2-ME2 did not modify SCL and MYC half-
lives (t1/2), as determined by cycloheximide chase in all 3 T-ALL 
thymocytes to 2-ME2. Furthermore, we observed that the non-
toxic doses of 2-ME2 did not affect the capacity of WT DN3 thy-
mocytes to generate DP cells in vitro (Supplemental Figure 4B), 
indicating that 2-ME2 did not block normal T cell differentiation 
within the tested range. In addition, we excluded the possibility 
that decreased pre-LSC viability could be secondary to stromal 
cell failure, since MS5-DL4 cell viability as well as DL4 surface 
expression was not affected by 2-ME2 at concentrations as high 
as 10 μM (Figure 3F).
2-ME2 exhibits structural similarity to DEXA (Figure 3C). 
We therefore compared their activities on the self-renewal of 
pre-LSCs following in vitro treatments with 1 μM 2-ME2 or 5 nM 
DEXA (Supplemental Figure 5A), corresponding to 75% inhibition 
in vitro (Figure 3E and Figure 1B). Pre-LSC frequency and activ-
ity were quantitatively assessed in vivo, by transplantation in irra-
diated congenic mice in limiting dilution assays (Supplemental 
Figure 5A). As shown in Figure 3G (and Supplemental Figure 5B), 
there was a striking difference between DEXA and 2-ME2. Even 
though both compounds were used at a dose of 75% inhibition in 
vitro, SCLtgLMO1tg pre-LSCs fully recovered from DEXA treatment 
in culture and their self-renewal activity in vivo was not altered, 
concurring with the view that pre-LSCs are spared by current 
treatment (4, 24). In contrast, 2-ME2 reduced pre-LSC frequency 
10-fold (Figure 3G and Supplemental Figure 5) and is therefore a 
drug candidate for T-ALL treatment.
2-ME2 inhibits SCL accumulation and transcriptional activ-
ity. At the molecular level, 2-ME2 but not DEXA decreased the 
expression of the SCL-dependent self-renewal genes (14) Lyl1 and 
Hhex without affecting mRNA levels of SCL (Figure 4A). Since 
pre-LSC self-renewal activity depends on the capacity of SCL 
to activate transcription (14), we next addressed the question of 
whether 2-ME2 inhibits SCL transcription activity, using a quan-
titative reporter assay (39, 40). We observed that 2-ME2 but not 
DEXA inhibited SCL activity in transient transcription assays (Fig-
ure 4B), consistent with the suppression of endogenous SCL tar-
get genes in pre-LSCs (Figure 4A). These results concur with our 
functional studies (Figure 3G) and indicated that 2-ME2 inhibits 
pre-LSC self-renewal activity via inhibition of SCL.
Recent evidence suggests an important nonmitotic function 
of 2-ME2, in preventing the nuclear accumulation of transcrip-
tion factors or DNA repair proteins (41, 42). We therefore quanti-
tated SCL at the single-cell level by flow cytometry and found that 
2-ME2 caused a dose-dependent inhibition of the human SCL 
oncoprotein in SCLtgLMO1tg pre-LSCs (Figure 4C). We examined 
the fate of the SCL protein by live cell imaging throughout the time 
exposure to 2-ME2. To this end, we delivered SCL-GFP into HeLa 
cells. We then followed GFP expression in individual cells in the 
presence or absence of 2-ME2 for 16 hours, a time point chosen 
based on HeLa full viability in drug-treated cultures (Supplemen-
tal Figure 6A). SCL-GFP expression in the nucleus of 2-ME2–
treated cells decreased steadily compared with that in untreated 
cells (Figure 4, D and E, top panels, and Supplemental Figure 6B). 
In contrast, 2-ME2 treatment of HeLa cells stably expressing the 
nuclear protein histone H2B-RFP did not modify the level of RFP 
expression during the same time lapse (Figure 4, D and E, bottom 
panels, and Supplemental Figure 6C), showing that 2-ME2 specifi-
cally targets SCL accumulation.
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2-ME2–treated HSPCs remain functional. Finally, in vitro treat-
ment with 2-ME2 for 4 days was sufficient to alter pre-LSC activ-
ity (Figure 3G), while normal HSPCs (KSL) retained self-renewal 
activity (Figure 6G) and multipotency (Supplemental Figure 11C) 
in serial transplantation assays. Therefore, this preclinical model 
of T-ALL indicates that normal HSPCs remain functional after 
in vivo exposure to 2-ME2, concurring with the reported lack of 
myelosuppression in clinical trials (36). Similarly, normal T cells 
were at least 4-fold less sensitive to 2-ME2, corresponding to an 
inability to downregulate MYC. In contrast, 2-ME2 reduced T-ALL 
blasts, leukemia-propagating cells, and pre-LSCs, revealing a sig-
nificant difference in chemosensitivity between normal cells and 
preleukemic/leukemic cells.
Primary human T-ALLs are sensitive to 2-ME2. Xenograft mod-
els of human T-ALL mimic disease relapse (52) and represent 
a powerful preclinical tool to directly test drug efficacy on pri-
mary leukemia cells in vivo (28). Purified leukemic blasts from 2 
T-ALL patients (14H025 and 14H148; Supplemental Table 3) were 
transplanted and expanded into immunocompromised NOD.Cg-
PrkdcscidIl2rgtmWjl/SzJ (referred to here as NSG) mice (Figure 7A) to 
test their sensitivities to 2-ME2 both in vitro and in vivo.
In vitro, both patient samples were sensitive to 2-ME2 treat-
ment in a dose-dependent manner but resistant to DEXA (Figure 
7B). At the molecular level, patient 14H025 exhibited SIL-TAL1 
chromosomal rearrangement and patient 14H148 did not (Supple-
mental Figure 12A and Supplemental Table 4). 2-ME2 treatment 
efficiently downregulated SCL protein levels in the SIL-TAL1 
patient sample 14H025 (Figure 7C), associated with the inhibition 
of 2 SCL-dependent target genes, LYL1 and NKX3.1 (45) (Figure 
7D, left panel). In contrast, LYL1 remained unaffected in the other 
patient sample, while NKX3.1 was decreased via an SCL-indepen-
dent mechanism (Figure 7D, right panel). MYC protein expres-
sion was detectable in both patient samples despite the absence 
of NOTCH1 mutations and of MYC rearrangement (Supplemental 
Table 4). Interestingly, MYC was decreased by 2-ME2 treatment in 
vitro in both patient samples (Figure 7C), associated with the inhi-
bition of the well-established MYC target gene ODC (reviewed in 
ref. 53) (Figure 7D). These observations indicate that 2-ME2 inhib-
its SCL and MYC functions in primary human T-ALL samples, as 
observed in the mouse model.
Finally, mice were transplanted and monitored for engraftment 
before treatment with 2-ME2 using osmotic minipumps (Figure 7E). 
Within 7 days, both samples engrafted in the BM with dissemina-
tion in the spleen, and 14H148 engrafted in the peripheral blood as 
well (Supplemental Figure 12B). Strikingly, treatment with 2-ME2 
downregulated SCL and MYC protein levels in vivo (Supplemen-
tal Figure 12C) and prevented T-ALL progression by significantly 
reducing the leukemic burden in the BM, spleen (Figure 7F), and 
peripheral blood (Supplemental Figure 12B) of recipient mice.
Together, these results indicate that 2-ME2 exhibits antileuke-
mic activity in primary human T-ALL blasts.
Discussion
In the present study, we bring evidence that pre-LSCs are more 
chemoresistant than leukemic blasts to conventional therapies 
because of their low proliferation rate. We developed a robust 
heterotypic assay for chemical screening of primary pre-LSCs in 
cell lines (Figure 5F and Supplemental Figure 9D). We therefore 
examined the possibility that 2-ME2 affects SCL and MYC trans-
lation. First we observed that the p70 ribosomal S6 kinase (S6K), 
a key downstream effector of mTORC1 signaling pathway (47), 
was active in all T-ALL cell lines (Figure 5G). Interestingly, 2-ME2 
inhibits S6 phosphorylation in KOPTK1 and P12-ICHIKAWA and 
to a lesser extent in JURKAT cells (Figure 5G), indicating that 
2-ME2 inhibits the mTORC1 pathway. Indeed, the translation of 
MYC mRNA was previously shown to be highly mTORC1-sensitive 
because of a long and structured 5′-UTR (48). By metabolic label-
ing with 35S-methionine (Figure 5H and Supplemental Figure 9E), 
we found that 2-ME2 strongly decreased MYC translation (Figure 
5H, right panel). These results reveal an unsuspected mechanism 
of 2-ME2 in inhibiting MYC translation. Since SCL translation was 
not significantly affected by 2-ME2 (Figure 5H, left panel), we 
infer that MYC and SCL translation has differential dependence 
on mTORC1 signaling.
2-ME2 kills leukemic blasts without affecting viability of nor-
mal HSPCs. We next showed that 2-ME2 inhibits SCL and MYC 
expression in fully transformed SCLtgLMO1tg leukemic blasts 
(Figure 5I) and addressed the question of whether 2-ME2 might 
also inhibit primary SCLtgLMO1tg leukemic cells. Comparison of 
the transcriptomes of murine SCL-LMO1–induced T-ALLs and of 
their normal counterparts points to the regulation of apoptosis as 
a top gene ontology category among SCL targets (Supplemental 
Figure 10A). We observed that 2-ME2 induced apoptosis in vitro 
both in pre-LSCs and in T-ALL blasts from SCLtgLMO1tg mice 
(Supplemental Figure 10B), consistent with an inhibition of SCL 
antiapoptotic function (49–51).
To study the effect of 2-ME2 on T-ALL in vivo, primary SCLtg 
LMO1tg T-ALL blasts were transplanted into 10 syngeneic mice 
(Figure 6A). After engraftment (Supplemental Figure 10C), which 
was as rapid and homogenous as in Figure 1E, mice were treated 
with 2-ME2 via implantation of osmotic minipumps (40 mg/kg/d) 
(Figure 6A). Compared with control mice receiving the vehicle 
only, 2-ME2 induced a profound reduction of leukemic blasts in 
the BM, thymus, spleen, and peripheral blood (Figure 6, B and 
C) and altered their capacities to initiate leukemia in secondary 
recipients (Figure 6D). In contrast, the analysis of normal host 
(CD45.1+) T cell compartments indicated that 2-ME2 did not block 
normal T cell differentiation in vivo (Supplemental Figure 11A), 
confirming our in vitro results (Supplemental Figure 4B). Despite 
high MYC levels in normal DN3 thymocytes, 2-ME2 did not affect 
MYC expression levels in these cells (Supplemental Figure 11B), 
concurring with their low sensitivities to 2-ME2 (Figure 3E). We 
therefore conclude that the SCL and LMO1 oncogenes sensitize 
DN3 cells to 2-ME2.
In parallel, we monitored how 2-ME2 affects residual normal 
stem/progenitor cells in the same mice. Host HSCs can be distin-
guished from transplanted cells on the basis of CD45 isoforms, 
as shown in Figure 6A. 2-ME2 modifies neither the frequency 
(Figure 6B) nor the absolute numbers (Figure 6E) of host HSPCs 
as defined by their c-Kit+Sca-1+lineage– (KSL) phenotype in vivo, 
contrasting with its dramatic effect on transplanted leukemic cells 
in the same mice. Moreover, 2-ME2–treated KSL cells retained 
proliferative and multilineage differentiation potentials when 
transplanted in secondary recipients (Figure 6F), indicating that 
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 5 8 0 jci.org   Volume 126   Number 12   December 2016
inhibitory effect on MYC. Concurring with the emerging role of 
MYC in AML (59, 60), perphenazine, the only phenothiazine hit in 
AML in the present study, was revealed as a top hit in a chemical 
screen for suppressors of MYC-induced T-ALL in zebrafish (35). 
Finally, the multiparametric screening assay described here could 
potentially allow for the identification of compounds that restore 
cell differentiation in T-ALL, as exemplified by the differentiation 
therapy achieved in acute promyelocytic leukemia (61).
The importance of regulated translation in T-ALL is under-
scored by the finding of recurring loss-of-function mutations in 
several ribosomal genes, RPL5, RPL10, and RPL22, in 10%–20% 
of pediatric T-ALL (62). In addition, PTEN deletion occurs in 20% 
of T-ALL, causing increased AKT (63) and a hyperactive mTORC1 
pathway. The translation of mRNA into polypeptide is mostly con-
trolled at the level of translation initiation, which is partly regu-
lated by the mTORC1 signaling pathway (47). While mTORC1 
controls global protein synthesis, it preferentially stimulates the 
translation of selected groups of mRNAs that contain relatively 
long and structured 5′-UTRs, including MYC (47). Here, we show 
that 2-ME2 strongly alters MYC translation without modifying 
SCL translation. We thus conclude that MYC and SCL have dif-
ferential dependence on the mTORC1 pathway. It remains to be 
determined whether this differential dependence could be impart-
ed by the structure of their 5′-UTRs, as reported for MYC (47). In 
summary, our observations place MYC as a highly sensitive target 
hit of 2-ME2, downstream of the mTORC1 pathway. Finally, MYC 
is frequently dysregulated in tumors and represents a major target 
in cancer therapy (64). In addition to inhibiting MYC transcription 
or activity (65), our observations support the view that it is possible 
to target MYC translation.
SCL controls HSC self-renewal activity under stress (50, 66–
68), and is redundant with Lyl1 during steady-state hematopoiesis 
(69). In contrast, SCL activation in thymocytes occurs in a context 
whereby other self-renewal genes are absent and therefore pre-
LSCs are “addicted” to SCL. Along the same line, Lyl1 upregula-
tion by Lmo2 in DN3 thymocytes occurs in a context whereby Scl 
is not expressed, and therefore Lyl1 is required for Lmo2 repro-
gramming activity (70). Similarly, Myc is critical for pre-LSC self-
renewal activity (14, 56), whereas Myc is redundant in HSCs (71), 
indicating that targeting MYC will spare normal HSCs. Our results 
do not rule out the possibility that normal stem/progenitor cells 
express a 2-ME2–resistant isoform of tubulin, β1-tubulin, proposed 
to protect patients from drug-induced myelosuppression (72). 
Nonetheless, we favor the idea that differential dependence on 
SCL and MYC levels distinguishes pre-LSCs from normal HSCs. 
Hence, decreasing SCL and MYC protein levels is synthetic lethal 
in pre-LSCs but not in HSCs that are endowed with a highly redun-
dant self-renewal node.
Chemical biology combined with the capacity for HTS pro-
vides unprecedented opportunities for drug discovery. Yet, despite 
the number of hits, there is currently a tendency for high drug attri-
tion rates when it comes to efficacy in clinical trials (73). Without 
ruling out the possibility that many factors could contribute to this 
high attrition rate, our results suggest that cell line–based screen-
ing as well as 2-dimensional screening assays may not yield much-
needed novel bioactive compounds. While these assays have been 
useful in identifying anticancer drugs, it is well known that cell 
an ex vivo assay mimicking a thymic-like microenvironment, and 
demonstrated the feasibility of this strategy for HTS. This strategy 
led us to identify an inhibitor that targets 2 central actors of the 
self-renewal node in pre-LSCs, SCL and MYC (14).
The development of new drugs targeting self-renewing (pre)
cancer stem cells could open new therapeutic opportunities for 
more selective treatments (6). In T-ALL, leukemic stem cells are 
capable of sustained leukemia propagation. Nonetheless, these 
cells are endowed with an evolving genetic landscape, carrying 
founder mutations as well as varying secondary mutations (24, 
52). In contrast, the emergence of self-renewing pre-LSCs via 
oncogene-induced reprogramming of normal thymocytes repre-
sents the earliest events in T-ALL (10, 12, 14) and in B cell acute 
lymphoblastic leukemia (7). Therefore, pre-LSCs represent the 
prime cellular target for novel drug development. In AML, these 
cells are believed to harbor landscaping mutations that remain 
stable in remission and relapse (4). These molecular studies also 
suggested that the cells that caused relapse are preleukemic HSCs 
that do not have the full complement of transforming events. 
Obviously, these cells must have escaped therapy (4). Nonethe-
less, direct evidence for differential chemosensitivity between 
pre-LSCs and leukemic blasts was hindered by the extreme rarity 
of these cells within the tumor bulk, as we now show that pre-LSCs 
are rapidly offset by more competitive, fully transformed leukemic 
blasts. We took advantage of the mouse model that recapitulates 
the evolution of the human disease to demonstrate that pre-LSCs 
are less sensitive than leukemic blasts to drugs that target prolifer-
ating cells, such as topoisomerase inhibitors, because of their low 
proliferative status. Similarly, leukemic blasts and pre-LSCs also 
exhibit differential sensitivities to radiation (54).
Our previous work indicates that self-renewing pre-LSCs 
depend both on the primary oncogenes and on the physiologi-
cal NOTCH1 pathway activated by the microenvironment (14). 
Interestingly, 2-ME2 specifically prevents SCL accumulation via 
a colchicine-independent mechanism, which differs from the col-
chicine-sensitive transport of HIF-1α into the nucleus via microtu-
bules (36). Moreover, 2-ME2 also decreased MYC protein levels, 
resulting in decreased expression of a prototypic MYC target gene, 
ODC. Based on our previous finding that MYC can substitute for 
NOTCH1 signaling to collaborate with SCL-LMO1 in thymocyte 
reprogramming (14), we conclude that 2-ME2 inhibits pre-LSCs 
by antagonizing their dependence on both SCL and the DL4-
NOTCH1 pathway. Moreover, we showed that 2-ME2 inhibits SCL 
and MYC targets in primary human T-ALL blasts and prevents 
their growth in a preclinical model of T-ALL.
Interestingly, gain of function of NOTCH1 is the most frequent 
genetic alteration in T-ALL that can be found in all molecular sub-
groups, defined by SCL/TAL1, LMO2, TLX1/3, HOXA, and MYB (9, 
26, 55). Given the necessary collaboration of NOTCH1-MYC with 
SCL-LMO1 in self-renewing pre-LSCs (14) and the importance of 
NOTCH1-MYC in T-ALL (56, 57), we surmise that inhibiting MYC 
could be lethal in other molecular T-ALL subgroups. In addition, 
inhibition of the NOTCH signaling pathway can antagonize gluco-
corticoid resistance, an adverse prognostic factor in ALL (58). We 
propose that 2-ME2 will be beneficial for the treatment of gluco-
corticoid-resistant primary or relapsed human T-ALL. In addition, 
2-ME2 may be of interest in AML treatment as well because of its 
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APC–anti-CD8, PE-Cy7–anti-CD25, and AF780–anti-CD44 at 4°C for 
15 minutes. The screen was then performed with an LSRII flow cytom-
eter equipped with an HTS module (BD Biosciences).
FACS analysis and cell sorting. Immunostaining was done as previ-
ously described (33). Dead cells were excluded by propidium iodide 
staining. Immunophenotype and apoptosis analysis was performed on 
an LSRII cytometer using DIVA (BD Biosciences) software. Cell sort-
ing was done using an FACSAria cytometer (BD Biosciences).
Congenic transplantation assay. Preleukemic thymocytes from 
donor mice (CD45.2+) were transplanted in i.v. into sublethally irradi-
ated (600 cGy) recipient mice (CD45.1+) (14). Thymic chimerism in 
the T lineage (Thy1.2+) was analyzed by flow cytometry (FACS) and 
illustrated by the percentage of donor-derived cells (% CD45.2+) 
found in the recipient thymus.
In vivo study of the effect of 2-ME2 on T-ALL development and HSC 
functions. T-ALL blasts (CD45.2+) from primary SCLtgLMO1tg thymo-
ma were injected i.v. into 10 sublethally irradiated CD45.1+ recipient 
mice (5 × 106 blasts per mouse). T-ALL reconstitution was assessed 
by FACS after BM aspiration, and mice were randomly selected for 
treatment with vehicle alone (50% DMSO; 50% PEG400) or 2-ME2 
(Bosche Scientific, M19071; 40 mg/kg/d). Osmotic minipumps (Alzet 
model 2001; 1 μl/h, 7 days) containing vehicle or 2-ME2 were loaded 
and primed at 37°C in 0.9% NaCl, 24 hours before their subcutane-
ous implantation, in accordance with the manufacturer’s instructions. 
T-ALL reconstitution was monitored in the thymus, BM, spleen, and 
blood, and engrafted T-ALL blasts from the BM were transplanted into 
secondary sublethally irradiated CD45.1+ mice. c-Kit+Sca-1+lineage– 
(KSL) cells from the BM of treated CD45.1+ mice were transplanted 
into secondary lethally irradiated CD45.2+ mice in parallel.
Xenogenic transplantation assay. T-ALL patient samples were 
selected for high blast counts (>90%) in the peripheral blood. T-ALL 
blasts were immunophenotyped using FITC–anti-hCD45, PE–anti-
hCD7, PE-Cy7–anti-hCD4, PE-Cy5–anti-hCD8, and APC–anti-
hCD34. Normal peripheral CD34+CD7– hematopoietic progenitors 
and mature CD4+/hi and CD8+/hi single-positive T cells (28) were 
excluded by cell sorting, and T-ALL blasts were transplanted and 
expanded by transplantation into sublethally irradiated (250 cGy) 8- 
to 12-week-old NOD-Scid IL2rgnull mice (NSG, Jackson Laboratory). 
Engrafted T-ALL blasts were collected from the spleen and the BM 
6–8 weeks after transplantation.
T-ALL blasts (CD45+CD7+) from primary NSG mice engrafted with 
each patient sample were injected i.v. into 10 secondary NSG mice (5 × 
106 blasts per mouse). T-ALL reconstitution was assessed by FACS after 
BM aspiration, and mice were randomly selected for treatment with the 
vehicle or 2-ME2 using osmotic minipumps as described above.
Limiting dilution assays. Preleukemic thymocytes were transplant-
ed into irradiated hosts at various cell doses. Mice were scored positive 
when T cell lineage reconstitution was more than 0.1% in the thymus. 
Pre-LSCs frequencies (range pre-LSC ± CI), also named competitive 
repopulating unit frequencies, were calculated by application of Pois-
son statistics using Limiting Dilution Analysis software (Stem Cell 
Technologies) (66).
Metabolic radiolabeling with 35S-methionine and immunopre-
cipitation. 4 × 107 JURKAT cells (106 cells/ml) were incubated 
overnight at 37°C, washed twice with 50 ml of l-methionine–free 
DMEM (Wisent Inc., 319-045-CL), and pretreated or not (DMSO) 
with 2-ME2 (3 μM) for 30 minutes. Cells were then centrifuged to 
fate is shaped by the local niche. It is therefore not surprising that 
the niche may also modify the chemosensitivity of primary leu-
kemic blasts (74). Our strategy led to the identification of a drug 
that inhibits both cell-autonomous and non–cell-autonomous 
pathways, acting in vitro and in vivo, while sparing normal HSCs. 
We propose that recapitulating tissue-like conditions (75–77) rep-
resents a promising avenue in the quest for new cancer therapies 
in other tumors.
Methods
Supplemental Methods are available online with this article; 
doi:10.1172/JCI86489DS1.
Human leukemia samples and cell lines. All AML and T-ALL samples 
were collected from the Maisonneuve-Rosemont Hospital of Montre-
al, Canada. Human JURKAT, KOPTK1, P12-ICHIKAWA, and HPB-
ALL cell lines were obtained from DSMZ, Germany.
Mice and ethics statement. All animals were maintained in 
pathogen-free conditions. The current study was performed using 
previously described SIL-SCL (referred to as SCLtg) and Lck-LMO1 
(referred to as LMO1tg) mice (15, 16, 33). All mouse lines were back-
crossed onto a C57BL6/J background for more than 12 generations. 
Mice cohorts were generated by cross-breeding, and their genotypes 
were verified by PCR.
Generation of MS5-DL4 stromal cell lines. Mouse stromal MS5 cells 
than can maintain in vitro both mouse and human long-term hema-
topoiesis were from K. Mori (Nagata University, Japan) (78) and were 
maintained as described previously (30). VSV-G–producing cells 
transfected with the human DLL4 cDNA (MHS4426-98361330, GE 
Healthcare) were used for gene transduction in MS5 cells (48 hours) 
as described previously (50, 66). Transduced MS5 cells were stained 
using rabbit anti-DLL4 (ab7280, Abcam), and 3 MS5 stromal cell lines 
were generated by cell sorting according to 3 levels of DL4 expression 
(low, medium, and high). Staining with the secondary antibody only 
was used for negative controls.
Chemical screen of small molecules on pre-LSCs. MS5-DL4 stro-
mal cells (2 × 103 per 40 μl per well) were seeded in 384-well plates 
in complete T cell medium described in the Supplemental Methods. 
Twenty-four hours later, DN thymocytes from thymi of 3-week-old 
preleukemic SCLtgLMO1tg mice were prepared by depletion of CD4+ 
and CD8+ thymocytes through immunomagnetic bead cell separation 
as previously described (66). DN3 (pre-LSC) thymocytes (5 × 103 per 
5 μl per well) were then purified and cocultured on seeded MS5-DL4 
stromal cells by cell sorting. Twenty-four hours later, cocultured pre-
LSCs were exposed to 1,904 individual FDA-approved and drug-like 
small molecules (Preswick; Biomol; Lopac/Sigma-Aldrich; Micro-
Source Discovery Systems) at a dose of 500 nM. Absolute numbers of 
DN3 cells were determined after 5 days of culture using flow cytom-
etry. In each plate, 16 wells containing pre-LSCs were treated with 1 
μM γ-secretase inhibitor (GSI) and 16 wells were treated with DMSO 
(vehicle) as positive and negative controls, respectively (Supplemen-
tal Figure 2). The inhibition (percentage) of pre-LSC viability by indi-
vidual compounds was calculated based on the absolute numbers of 
cells in the DN3 gate (Thy1+CD4–CD8–CD25+CD44–) recovered from 
3 different treatment conditions according to the formula 100 – ((test 
compound – median GSI) / (median vehicle – median GSI) × 100).
Pre-LSCs were stained by addition of 5 μl/well of PBS supple-
mented with 2% FBS containing PE–anti-Thy1.2, PE-Cy5–anti-CD4, 
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submersible transfer apparatus and polyvinylidene fluoride mem-
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Healthcare Life Science).
Statistics. Z′ value was calculated according to the formula 1 – [3 × (SD 
of positive control + SD of negative control)/(mean of positive control – 
mean of negative control)]. The theoretical maximum value for the Z′ fac-
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